2026 Q1 -tulosraportti
UUTTA
5 päivää sitten
‧29 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 633 | - | - | ||
| 100 | - | - | ||
| 493 | - | - | ||
| 7 | - | - | ||
| 893 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 359 497 | 359 497 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 359 497 | 359 497 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
2 t sitten2 t sittenFra DNB Carnegies POST-RESULTS NOTE * KDIGO guidelines likely the next trigger **Takeover a potential scenario. We see BioPorto as a potential acquisition target for large diagnostics companies. Based on historical transaction multiples in the Nordics, we believe such a deal could be executed at ~7x EV/sales or ~20x EV/EBITDA. On our 2032 estimates we calculate this would imply a ~DKK4.7–5.6/share equity value (discounted by a 16.5% WACC). ***Fair value range of DKK0.5–3.0 per share reiterated. Our valuation range is based on a risk-adjusted SOTP NPV (16.5% WACC, 1.4x beta and 5% liquidity premium): The upper end reflects an additional 10% annual revenue growth and 1% annual EBITDA margin expansion from our forecast over 2026–44e; the lower end assumes no FDA approval of ProNephro for adults. - Q1 review DownloadQ1 revenue was slightly below our estimate, but we note good operational execution and cost control. The cash position as of 8 April was DKK98m. 2026 guidance was maintained. We expect KDIGO guidelines in H2, which we see as the next potential share price trigger. We make minor estimate changes and reiterate our FV range of DKK0.5–3.0 per share.
·15 t sittenSimply Wall Street has on May 19 published an article with three promising European penny stocks. BioPorto is one of them.
·3 päivää sittenBioPorto (Investment case): Q1 2026, advancement on the three pillars central to the long-term potential https://www.inderes.dk/en/research/bioporto-investment-case-q1-2026-advancement-on-the-three-pillars-central-to-the-long-term-potential?utm_source=nordnet&utm_medium=integration·1 päivä sittenJohn Kellum is co-chairman at KDIGO, and his words carry great weight with KDIGO's constituents, and he has stated that AKI should have a strong recommendation after cardiac surgery. A strong recommendation is a 1st degree recommendation. John Kellum has used Bioporto's NGAL test in his research. John Kellum has evidence that Bioporto's NGAL test saves lives after cardiac surgery. Furthermore, John Kellum has also just received an honorable award for his work with the above. Just for the sake of good order, if you want proof that John Kellum has used the NGAL test, you can just read through the documents I previously attached as a link to you. But since you are not aware that it is as certain as amen in church that Bioporto will receive a strong recommendation (1st degree recommendation), then you haven't read it, have you. https://www.linkedin.com/in/john-kellum-306b692b1/recent-activity/all/?trk=eml-email_next_best_action_digest_01-klgkMNTbQEuzEzzoxI2d1g%3D%3D-0-klgkMNTbQEuzEzzoxI2d1g%3D%3D- ·3 päivää sittenJust want to note that BP's increases historically have been driven by hysteria! These days/weeks/month(s) something "calmly" increasing is happening. And that, I think, is a sign of health. It doesn't jump by, for example, 75 øre. It seems to ground itself a bit à la two steps forward and one back. It looks calmer. It looks promising. Regards. Bagerbrød
·22.5.The price finally seems to be turning around, as there are green %-s for the last 6 months, but there is still room for improvement. 2.0 must be the next target this year.·22.5.It depends on when KDIGO comes out with a 1st degree recommendation for the NGAL test. Those of us who have kept the stock in our portfolio, and have bought at the bottom, we can just lean back and watch all those who only buy when the announcement is made public. Bioporto has announced that they have already acquired 4 new hospitals in Q1. The reason why these hospitals have already integrated the NGAL test in Q1 and not in Q4, (see CBs explanation in Webcast Q 4 2025) is due to KDIGO's draft and the various announcements before the hearing concluded. We know that FDA will approve the adult test, it's just a question of when.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
UUTTA
5 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 2 t sitten2 t sittenFra DNB Carnegies POST-RESULTS NOTE * KDIGO guidelines likely the next trigger **Takeover a potential scenario. We see BioPorto as a potential acquisition target for large diagnostics companies. Based on historical transaction multiples in the Nordics, we believe such a deal could be executed at ~7x EV/sales or ~20x EV/EBITDA. On our 2032 estimates we calculate this would imply a ~DKK4.7–5.6/share equity value (discounted by a 16.5% WACC). ***Fair value range of DKK0.5–3.0 per share reiterated. Our valuation range is based on a risk-adjusted SOTP NPV (16.5% WACC, 1.4x beta and 5% liquidity premium): The upper end reflects an additional 10% annual revenue growth and 1% annual EBITDA margin expansion from our forecast over 2026–44e; the lower end assumes no FDA approval of ProNephro for adults. - Q1 review DownloadQ1 revenue was slightly below our estimate, but we note good operational execution and cost control. The cash position as of 8 April was DKK98m. 2026 guidance was maintained. We expect KDIGO guidelines in H2, which we see as the next potential share price trigger. We make minor estimate changes and reiterate our FV range of DKK0.5–3.0 per share.
- ·15 t sittenSimply Wall Street has on May 19 published an article with three promising European penny stocks. BioPorto is one of them.
- ·3 päivää sittenBioPorto (Investment case): Q1 2026, advancement on the three pillars central to the long-term potential https://www.inderes.dk/en/research/bioporto-investment-case-q1-2026-advancement-on-the-three-pillars-central-to-the-long-term-potential?utm_source=nordnet&utm_medium=integration·1 päivä sittenJohn Kellum is co-chairman at KDIGO, and his words carry great weight with KDIGO's constituents, and he has stated that AKI should have a strong recommendation after cardiac surgery. A strong recommendation is a 1st degree recommendation. John Kellum has used Bioporto's NGAL test in his research. John Kellum has evidence that Bioporto's NGAL test saves lives after cardiac surgery. Furthermore, John Kellum has also just received an honorable award for his work with the above. Just for the sake of good order, if you want proof that John Kellum has used the NGAL test, you can just read through the documents I previously attached as a link to you. But since you are not aware that it is as certain as amen in church that Bioporto will receive a strong recommendation (1st degree recommendation), then you haven't read it, have you. https://www.linkedin.com/in/john-kellum-306b692b1/recent-activity/all/?trk=eml-email_next_best_action_digest_01-klgkMNTbQEuzEzzoxI2d1g%3D%3D-0-klgkMNTbQEuzEzzoxI2d1g%3D%3D
- ·3 päivää sittenJust want to note that BP's increases historically have been driven by hysteria! These days/weeks/month(s) something "calmly" increasing is happening. And that, I think, is a sign of health. It doesn't jump by, for example, 75 øre. It seems to ground itself a bit à la two steps forward and one back. It looks calmer. It looks promising. Regards. Bagerbrød
- ·22.5.The price finally seems to be turning around, as there are green %-s for the last 6 months, but there is still room for improvement. 2.0 must be the next target this year.·22.5.It depends on when KDIGO comes out with a 1st degree recommendation for the NGAL test. Those of us who have kept the stock in our portfolio, and have bought at the bottom, we can just lean back and watch all those who only buy when the announcement is made public. Bioporto has announced that they have already acquired 4 new hospitals in Q1. The reason why these hospitals have already integrated the NGAL test in Q1 and not in Q4, (see CBs explanation in Webcast Q 4 2025) is due to KDIGO's draft and the various announcements before the hearing concluded. We know that FDA will approve the adult test, it's just a question of when.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 633 | - | - | ||
| 100 | - | - | ||
| 493 | - | - | ||
| 7 | - | - | ||
| 893 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 359 497 | 359 497 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 359 497 | 359 497 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
UUTTA
5 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 2 t sitten2 t sittenFra DNB Carnegies POST-RESULTS NOTE * KDIGO guidelines likely the next trigger **Takeover a potential scenario. We see BioPorto as a potential acquisition target for large diagnostics companies. Based on historical transaction multiples in the Nordics, we believe such a deal could be executed at ~7x EV/sales or ~20x EV/EBITDA. On our 2032 estimates we calculate this would imply a ~DKK4.7–5.6/share equity value (discounted by a 16.5% WACC). ***Fair value range of DKK0.5–3.0 per share reiterated. Our valuation range is based on a risk-adjusted SOTP NPV (16.5% WACC, 1.4x beta and 5% liquidity premium): The upper end reflects an additional 10% annual revenue growth and 1% annual EBITDA margin expansion from our forecast over 2026–44e; the lower end assumes no FDA approval of ProNephro for adults. - Q1 review DownloadQ1 revenue was slightly below our estimate, but we note good operational execution and cost control. The cash position as of 8 April was DKK98m. 2026 guidance was maintained. We expect KDIGO guidelines in H2, which we see as the next potential share price trigger. We make minor estimate changes and reiterate our FV range of DKK0.5–3.0 per share.
- ·15 t sittenSimply Wall Street has on May 19 published an article with three promising European penny stocks. BioPorto is one of them.
- ·3 päivää sittenBioPorto (Investment case): Q1 2026, advancement on the three pillars central to the long-term potential https://www.inderes.dk/en/research/bioporto-investment-case-q1-2026-advancement-on-the-three-pillars-central-to-the-long-term-potential?utm_source=nordnet&utm_medium=integration·1 päivä sittenJohn Kellum is co-chairman at KDIGO, and his words carry great weight with KDIGO's constituents, and he has stated that AKI should have a strong recommendation after cardiac surgery. A strong recommendation is a 1st degree recommendation. John Kellum has used Bioporto's NGAL test in his research. John Kellum has evidence that Bioporto's NGAL test saves lives after cardiac surgery. Furthermore, John Kellum has also just received an honorable award for his work with the above. Just for the sake of good order, if you want proof that John Kellum has used the NGAL test, you can just read through the documents I previously attached as a link to you. But since you are not aware that it is as certain as amen in church that Bioporto will receive a strong recommendation (1st degree recommendation), then you haven't read it, have you. https://www.linkedin.com/in/john-kellum-306b692b1/recent-activity/all/?trk=eml-email_next_best_action_digest_01-klgkMNTbQEuzEzzoxI2d1g%3D%3D-0-klgkMNTbQEuzEzzoxI2d1g%3D%3D
- ·3 päivää sittenJust want to note that BP's increases historically have been driven by hysteria! These days/weeks/month(s) something "calmly" increasing is happening. And that, I think, is a sign of health. It doesn't jump by, for example, 75 øre. It seems to ground itself a bit à la two steps forward and one back. It looks calmer. It looks promising. Regards. Bagerbrød
- ·22.5.The price finally seems to be turning around, as there are green %-s for the last 6 months, but there is still room for improvement. 2.0 must be the next target this year.·22.5.It depends on when KDIGO comes out with a 1st degree recommendation for the NGAL test. Those of us who have kept the stock in our portfolio, and have bought at the bottom, we can just lean back and watch all those who only buy when the announcement is made public. Bioporto has announced that they have already acquired 4 new hospitals in Q1. The reason why these hospitals have already integrated the NGAL test in Q1 and not in Q4, (see CBs explanation in Webcast Q 4 2025) is due to KDIGO's draft and the various announcements before the hearing concluded. We know that FDA will approve the adult test, it's just a question of when.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 633 | - | - | ||
| 100 | - | - | ||
| 493 | - | - | ||
| 7 | - | - | ||
| 893 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 359 497 | 359 497 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 359 497 | 359 497 | 0 | 0 |